News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,775 Results
Type
Article (2558)
Company Profile (3)
Press Release (11214)
Section
Business (5168)
Career Advice (72)
Deals (872)
Drug Delivery (7)
Drug Development (2319)
Employer Resources (6)
FDA (404)
Job Trends (698)
News (8619)
Policy (974)
Tag
Academia (40)
Allergies (4)
Alliances (1327)
ALS (6)
Alzheimer's disease (17)
Antibody-drug conjugate (ADC) (6)
Approvals (402)
Artificial intelligence (7)
Autoimmune disease (4)
Bankruptcy (6)
Best Places to Work (480)
Breast cancer (3)
Cancer (36)
Career advice (53)
Cell therapy (6)
Clinical research (1840)
Collaboration (18)
COVID-19 (201)
C-suite (10)
Data (39)
Diabetes (10)
Diagnostics (55)
Drug discovery (5)
Drug pricing (6)
Earnings (1243)
Editorial (4)
Employer resources (5)
Events (1004)
Executive appointments (27)
FDA (419)
Funding (19)
Gene therapy (6)
GLP-1 (69)
Government (216)
Healthcare (285)
Immunology and inflammation (9)
Indications (3)
Infectious disease (207)
Inflammatory bowel disease (6)
Interviews (12)
IPO (205)
Job creations (241)
Job search strategy (53)
Layoffs (39)
Legal (236)
Lung cancer (5)
Lymphoma (5)
Manufacturing (7)
Medical device (53)
Medtech (53)
Mergers & acquisitions (671)
Metabolic disorders (21)
Multiple sclerosis (12)
Neurodegenerative disease (6)
Neuroscience (40)
NextGen: Class of 2025 (158)
Non-profit (65)
Northern California (100)
Obesity (9)
Opinion (27)
People (2225)
Phase I (507)
Phase II (692)
Phase III (877)
Pipeline (30)
Podcasts (8)
Postmarket research (162)
Preclinical (151)
Radiopharmaceuticals (9)
Rare diseases (17)
Real estate (160)
Regulatory (614)
Research institute (43)
Resumes & cover letters (12)
RSV (5)
Series B (5)
Southern California (28)
Startups (134)
The Weekly (8)
United States (276)
Vaccines (53)
Venture capitalists (3)
Weight loss (9)
Date
Today (6)
Last 7 days (21)
Last 30 days (74)
Last 365 days (761)
2025 (74)
2024 (753)
2023 (759)
2022 (1570)
2021 (1380)
2020 (1158)
2019 (777)
2018 (636)
2017 (830)
2016 (748)
2015 (896)
2014 (564)
2013 (494)
2012 (502)
2011 (503)
2010 (466)
Location
Africa (55)
Asia (769)
Australia (92)
California (132)
Canada (15)
China (24)
Europe (4186)
Florida (5)
Maryland (6)
Massachusetts (40)
New Jersey (14)
New York (54)
North Carolina (4)
Northern California (100)
Pennsylvania (14)
South America (60)
Southern California (28)
13,775 Results for "sanofi".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Sanofi Earnings Driven by Dupixent, New RSV Vaccine as Hunt for Deals Continues
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
January 30, 2025
·
2 min read
·
Dan Samorodnitsky
Podcast
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.
October 23, 2024
·
1 min read
·
Heather McKenzie
Radiopharmaceuticals
Sanofi Inks $326M Radiopharma Deal With Orano
Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the radioligand space with a $110 million licensing deal with Orano Med and Texas biotech RadioMedix.
October 17, 2024
·
2 min read
·
Tristan Manalac
Healthcare
As Sanofi Preps Consumer Healthcare Sale, Here’s a Look Back at Similar High-Profile Deals
Sanofi looks to follow a deep history of Big Pharma offloading their consumer healthcare businesses.
October 16, 2024
·
6 min read
·
Annalee Armstrong
Deals
Sanofi Seals Deal With Private Equity Firm for 50% Stake in Consumer Healthcare Unit
Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French government taking a stake as well to ensure the business remains in the county.
October 21, 2024
·
2 min read
·
Annalee Armstrong
FDA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.
September 27, 2024
·
2 min read
·
Kate Goodwin
Multiple sclerosis
Roche Touts Phase II MS Data on Heels of Sanofi’s Late-Stage Stumbles
Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage win in relapsing multiple sclerosis, demonstrating near-total elimination of disease activity.
September 4, 2024
·
2 min read
·
Tristan Manalac
Approvals
Sanofi Secures First-Line Nod for Sarclisa in Multiple Myeloma, Tees Up Competition With J&J
With Friday’s approval, Sanofi’s anti-CD38 antibody Sarclisa will go head-to-head with the first such therapy for multiple myeloma, Johnson & Johnson’s Darzalex, which raked in nearly $10 billion last year.
September 23, 2024
·
2 min read
·
Tristan Manalac
Earnings
Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.
October 25, 2024
·
3 min read
·
Tristan Manalac
Editorial
Roche and Sanofi MS Trials Show Potential, Challenges of Oral BTK Inhibitors
Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two late-stage relapsing MS studies.
September 6, 2024
·
3 min read
·
Greg Slabodkin
1 of 1,378
Next
